Progyny downgraded by Canaccord Genuity with a new price target
$PGNY
Misc Health and Biotechnology Services
Health Care
Canaccord Genuity downgraded Progyny from Buy to Hold and set a new price target of $24.00 from $37.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $17.00 | Overweight → Neutral | Analyst |
| 11/13/2024 | $26.00 → $19.00 | Buy → Hold | Truist |
| 9/19/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | $37.00 → $24.00 | Buy → Hold | Canaccord Genuity |
| 8/7/2024 | $31.00 → $25.00 | Outperform → Market Perform | Leerink Partners |
| 8/7/2024 | Buy → Neutral | BTIG Research | |
| 7/16/2024 | $36.00 | Mkt Outperform | JMP Securities |
| 5/10/2024 | Overweight → Sector Weight | KeyBanc Capital Markets |
Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl
Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2024 ("the fourth quarter of 2024" and "the full year", respectively) as compared to the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the prior year period",
Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00
Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously
JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform
4 - Progyny, Inc. (0001551306) (Issuer)
3 - Progyny, Inc. (0001551306) (Issuer)
3 - Progyny, Inc. (0001551306) (Issuer)
Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio repl
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced the acquisition of BenefitBump, a comprehensive parental leave benefits navigation program for new and growing families. This addition enhances Progyny's fertility and family building offering, extending the company's ability to further serve the needs of families on their journey from pregnancy to early childhood and beyond. With 90% of parents seeking greater support to manage responsibilities at work and home, Progyny's enhanced suite of solutions aims to reduce member stress, improve recruitment, return-to-work and
10-Q - Progyny, Inc. (0001551306) (Filer)
8-K - Progyny, Inc. (0001551306) (Filer)
SCHEDULE 13G - Progyny, Inc. (0001551306) (Subject)